Trial · NCT07482020
SGLT2i Improve Left Atrial Function in Patients With Paroxysmal Atrial Fibrillation, Hypertension and Abnormal Glucose Metabolism
NCT07482020, Phase 2, Recruiting, Huashan Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. SGLT2i Improve Left Atrial Function in Patients With Paroxysmal Atrial Fibrillation, Hypertension and Abnormal Glucose Metabolism. Trials, record NCT07482020. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07482020
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- SGLT2i Improve Left Atrial Function in Patients With Paroxysmal Atrial Fibrillation, Hypertension and Abnormal Glucose Metabolism
- NCT number
- NCT07482020
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 66 participants, estimated
- Lead sponsor
- Huashan Hospital
- Conditions
- Atrial Fibrillation (AF), Hypertension
- Interventions
- SGLT-2 inhibitors, Placebo
- First posted
- 2026-03-19
- Last updated
- 2026-03-19
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | LA strain （LASI） | from enrollment to the end of treatment at 12 months | Using three-dimensional speckle tracking technology to measure longitudinal strain during the reservoir phase (LASr).Using TDI to measure E/e'. The LASI is calculated by these two parameter and can indicate left atrial strain. |
| Secondary | circumferential strain (LASr-c) | From enrollment to the end of treatment at 12 months | Using three-dimensional speckle tracking technology to measure |
| Secondary | conduit phase (LAScd) | From enrollment to the end of treatment at 12 months | Using three-dimensional speckle tracking technology to measure |
| Secondary | hospitalization due to heart failure | From enrollment to the end of treatment at 12 months | Record events of subjects visiting or being hospitalized due to heart failure during the follow-up period. This endpoint includes patients who present with symptoms such as dyspnea, fatigue, and orthopnea during the follow-up period, and have an NT-proBNP level greater than 300pg/ml detected in the emergency department, outpatient clinic, or inpatient department, with a documented diagnosis. |
| Secondary | changes in blood pressure | From enrollment to the end of treatment at 12 months | Patients undergo standardized office blood pressure monitoring (OBPM) using automated oscillometric devices or manual sphygmomanometry with appropriate cuff sizes. Measurements are obtained after 5 minutes of seated rest, with feet flat on the floor and arm supported at heart level. Two to three readings are taken 1-2 minutes apart, and the average is recorded. Take the blood pressure test for every month. Ensure that the medication use of the enrolled subjects remains unchanged during the follow-up period. |
| Secondary | change in blood glucose | From enrollment to the end of treatment at 12 months | Patients undergo venous blood sampling after 8-12 hours of overnight fasting. Measurements are performed using standardized enzymatic methods (hexokinase or glucose oxidase). HbA1c is measured via high-performance liquid chromatography (HPLC) or immunoassay. FPG monthly; HbA1c every 3 months. Ensure that the medication use of the enrolled subjects remains unchanged during the follow-up period. |
| Secondary | Change in lipid metabolism | from enrollment to the end of treatment at 12 months | Fasting venous blood sampling (12-14 hours overnight fast) followed by Enzymatic colorimetric assays for TC, TG, and HDL-C. Testing is done every month. Ensure that the medication use of the enrolled subjects remains unchanged during the follow-up period. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07482020
GET https://conductscience.org/api/trials/v1/NCT07482020/registered